Assessments of CYP‑inhibition‑based drug–drug interaction between vonoprazan and poziotinib in vitro and in vivo

References

• Benet LZ, Bowman CM, Koleske ML, Rinaldi CL, Sodhi JK. 2019. Understanding drug-drug interaction and pharmacogenomic changes in pharmacokinetics for metabolized drugs. J Pharmacokinet Pharmacodyn. 46(2):155–163.
   PubMed Web of Science ®Google Scholar
• Dungo RT, Keating GM. 2013. Afatinib: first global approval. Drugs. 73(13):1503–1515.
   PubMed Web of Science ®Google Scholar
• Echizen H. 2016. The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 55(4):409–418.
   PubMed Web of Science ®Google Scholar
• El Rouby N, Lima JJ, Johnson JA. 2018. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 14(4):447–460.
   PubMed Web of Science ®Google Scholar
• Eriksson LC. 1978. Preparation of liver microsomes with high recovery of endoplasmic reticulum and a low grade of contamination. Biochim Biophys Acta. 508(1):155–164.
   PubMedGoogle Scholar
• Gandhi S, Fleet JL, Bailey DG, McArthur E, Wald R, Rehman F, Garg AX. 2013. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. JAMA. 310(23):2544–2553.
   PubMed Web of Science ®Google Scholar
• Garnock-Jones KP. 2015. Vonoprazan: first global approval. Drugs. 75(4):439–443.
   PubMed Web of Science ®Google Scholar
• Hiraide M, Minowa Y, Nakano Y, Suzuki K, Shiga T, Nishio M, Miyoshi J, Takahashi H, Hama T. 2019. Drug interactions between tyrosine kinase inhibitors (gefitinib and erlotinib) and warfarin: assessment of international normalized ratio elevation characteristics and in vitro CYP2C9 activity. J Oncol Pharm Pract. 25(7):1599–1607.
   PubMed Web of Science ®Google Scholar
• Hu LM, Dai DP, Hu GX, Yang JF, Xu RA, Yang LP, Qian JC, Ge RS, Cai JP. 2012. Genetic polymorphisms and novel allelic variants of CYP2C19 in the Chinese Han population. Pharmacogenomics. 13(14):1571–1581.
   PubMed Web of Science ®Google Scholar
• Ji W, Shen J, Wang B, Chen F, Meng D, Wang S, Dai D, Zhou Y, Wang C, Zhou Q. 2021. Effects of dacomitinib on the pharmacokinetics of poziotinib in vivo and in vitro. Pharm Biol. 59(1):457–464.
   PubMed Web of Science ®Google Scholar
• Kato H. 2020. Computational prediction of cytochrome P450 inhibition and induction. Drug Metab Pharmacokinet. 35(1):30–44.
   PubMed Web of Science ®Google Scholar
• Kim E, Kim H, Suh K, Kwon S, Lee G, Park NH, Hong J. 2013. Metabolite identification of a new tyrosine kinase inhibitor, HM781-36B, and a pharmacokinetic study by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 27(11):1183–1195.
   PubMed Web of Science ®Google Scholar
• Kim JY, Park K, Im SA, Jung KH, Sohn J, Lee KS, Kim JH, Yang Y, Park YH. 2020. Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib. Breast Cancer Res Treat. 184(3):743–753.
   PubMed Web of Science ®Google Scholar
• Kim TY, Han HS, Lee KW, Zang DY, Rha SY, Park YI, Kim JS, Lee KH, Park SH, Song EK, et al. 2019. A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer. Gastric Cancer. 22(6):1206–1214.
   PubMed Web of Science ®Google Scholar
• Kogame A, Takeuchi T, Nonaka M, Yamasaki H, Kawaguchi N, Bernards A, Tagawa Y, Morohashi A, Kondo T, Moriwaki T, et al. 2017. Disposition and metabolism of TAK-438 (vonoprazan fumarate), a novel potassium-competitive acid blocker, in rats and dogs. Xenobiotica. 47(3):255–266.
   PubMed Web of Science ®Google Scholar
• Lee B, Ji HK, Lee T, Liu KH. 2015. Simultaneous screening of activities of five cytochrome P450 and four uridine 5′-diphospho-glucuronosyltransferase enzymes in human liver microsomes using cocktail incubation and liquid chromatography-tandem mass spectrometry. Drug Metab Dispos. 43(7):1137–1146.
   PubMed Web of Science ®Google Scholar
• Liu L, Sun S, Rui H, Li X. 2017. In vitro inhibitory effects of dihydromyricetin on human liver cytochrome P450 enzymes. Pharm Biol. 55(1):1868–1874.
   PubMed Web of Science ®Google Scholar
• Ma J, Wang S, Zhang M, Zhang Q, Zhou Y, Lin C, Lin G, Wang X. 2015. Simultaneous determination of bupropion, metroprolol, midazolam, phenacetin, omeprazole and tolbutamide in rat plasma by UPLC-MS/MS and its application to cytochrome P450 activity study in rats. Biomed Chromatogr. 29(8):1203–1212.
   PubMed Web of Science ®Google Scholar
• Marabotto E, Ziola S, Savarino V, Giannini EG, Furnari M, Bodini G, Zingone F, Ghisa M, Barberio B, Zentilin P, et al. 2020. Vonoprazan fumarate for the treatment of gastric ulcers: a short review on emerging data. Clin Exp Gastroenterol. 13:99–104.
   PubMed Web of Science ®Google Scholar
• Martinucci I, Blandizzi C, Bodini G, Marabotto E, Savarino V, Marchi S, de Bortoli N, Savarino E. 2017. Vonoprazan fumarate for the management of acid-related diseases. Expert Opin Pharmacother. 18(11):1145–1152.
   PubMed Web of Science ®Google Scholar
• Mori H, Suzuki H. 2019. Role of acid suppression in acid-related diseases: proton pump inhibitor and potassium-competitive acid blocker. J Neurogastroenterol Motil. 25(1):6–14.
   PubMed Web of Science ®Google Scholar
• Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. 2016. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 65(9):1439–1446.
   PubMed Web of Science ®Google Scholar
• Nishihara M, Yamasaki H, Czerniak R, Jenkins H. 2019. In vitro assessment of potential for CYP-inhibition-based drug-drug interaction between vonoprazan and clopidogrel. Eur J Drug Metab Pharmacokinet. 44(2):217–227.
   PubMed Web of Science ®Google Scholar
• Oshima T, Miwa H. 2018. Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases. J Neurogastroenterol Motil. 24(3):334–344.
   PubMed Web of Science ®Google Scholar
• Prommer E. 2004. Gefitinib: a new agent in palliative care. Am J Hosp Palliat Care. 21(3):222–227.
   PubMedGoogle Scholar
• Prout W. 1974. On the nature of the acid and saline matters usually existing in the stomachs of animals. Gut. 15(1):45.1–49.1.
   PubMed Web of Science ®Google Scholar
• Rosell R, Cardona Zorrilla AF. 2021. Poziotinib treatment in intractable NSCLC: epidermal growth factor receptor and human epidermal growth factor receptor 2 exon 20 insertion mutation disease. Eur J Cancer. 149:233–234.
   PubMed Web of Science ®Google Scholar
• Sachs G, Shin JM, Munson K, Scott DR. 2014. Gastric acid-dependent diseases: a twentieth-century revolution. Dig Dis Sci. 59(7):1358–1369.
   PubMed Web of Science ®Google Scholar
• Sevrioukova IF, Poulos TL. 2015. Current approaches for investigating and predicting cytochrome P450 3A4-ligand interactions. Adv Exp Med Biol. 851:83–105.
   PubMed Web of Science ®Google Scholar
• Shen J, Wang B, Wang S, Chen F, Meng D, Jiang H, Zhou Y, Geng P, Zhou Q, Liu B. 2020. Effects of voriconazole on the pharmacokinetics of vonoprazan in rats. Drug Des Dev Ther. 14:2199–2206.
   PubMed Web of Science ®Google Scholar
• Shin JM, Inatomi N, Munson K, Strugatsky D, Tokhtaeva E, Vagin O, Sachs G. 2011. Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamin e monofumarate (TAK-438. J Pharmacol Exp Ther. 339(2):412–420.
   PubMed Web of Science ®Google Scholar
• Shin JM, Kim N. 2013. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 19(1):25–35.
   PubMed Web of Science ®Google Scholar
• Shirley M. 2018. Dacomitinib: first global approval. Drugs. 78(18):1947–1953.
   PubMed Web of Science ®Google Scholar
• Sugano K. 2018. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Therap Adv Gastroenterol. 11:1756283x17745776.
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Hira D, Murata M, Kawai T, Terada T. 2020. Effect of antibiotic susceptibility and CYP3A4/5 and CYP2C19 genotype on the outcome of vonoprazan-containing Helicobacter pylori eradication therapy. Antibiotics. 9(10):645.
   Google Scholar
• Suzuki A, Iida I, Hirota M, Akimoto M, Higuchi S, Suwa T, Tani M, Ishizaki T, Chiba K. 2003. CYP isoforms involved in the metabolism of clarithromycin in vitro: comparison between the identification from disappearance rate and that from formation rate of metabolites. Drug Metab Pharmacokinet. 18(2):104–113.
   PubMedGoogle Scholar
• Suzuki Y, Yoshihashi T, Takahashi K, Furuya K, Ohkohchi N, Oda T, Homma M. 2021. Drug-drug interaction between tacrolimus and vonoprazan in kidney transplant recipients. JCM. 10(17):3964.
   Google Scholar
• Tyzack JD, Kirchmair J. 2019. Computational methods and tools to predict cytochrome P450 metabolism for drug discovery. Chem Biol Drug Des. 93(4):377–386.
   PubMed Web of Science ®Google Scholar
• Wang J, Chen F, Jiang H, Xu J, Meng D, Geng P, Dai D, Hu J, Zhou Y, Zhou Q, et al. 2020. Inhibition and induction by poziotinib of different rat cytochrome P450 enzymes in vivo and in an in vitro cocktail method. Front Pharmacol. 11:593518.
   PubMed Web of Science ®Google Scholar
• Wang Y, Jin Y, Yun X, Wang M, Dai Y, Xia Y. 2018. Co-administration with simvastatin or lovastatin alters the pharmacokinetic profile of sinomenine in rats through cytochrome P450-mediated pathways. Life Sci. 209:228–235.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang C, Wang S, Zhou Q, Dai D, Shi J, Xu X, Luo Q. 2020. Cytochrome P450-based drug-drug interactions of vonoprazan in vitro and in vivo. Front Pharmacol. 11:53.
   PubMed Web of Science ®Google Scholar
• Werk AN, Cascorbi I. 2014. Functional gene variants of CYP3A4. Clin Pharmacol Ther. 96(3):340–348.
   PubMed Web of Science ®Google Scholar
• Yamasaki H, Kawaguchi N, Nonaka M, Takahashi J, Morohashi A, Hirabayashi H, Moriwaki T, Asahi S. 2017. In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 47(12):1027–1034.
   PubMed Web of Science ®Google Scholar
• Yoneyama T, Teshima K, Jinno F, Kondo T, Asahi S. 2016. A validated simultaneous quantification method for vonoprazan (TAK-438F) and its 4 metabolites in human plasma by the liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 1015–1016:42–49.
   PubMed Web of Science ®Google Scholar